Chronic Liver Disease ✅

Chronic Liver Disease (CLD) refers to progressive liver injury lasting >6 months, often asymptomatic until advanced. It encompasses fibrosis, cirrhosis, portal hypertension, and hepatocellular carcinoma (HCC) risk. Early detection, identification of cause, and risk stratification are essential to prevent complications and guide referral, consistent with NICE guidance (NG50, NG145, NG196, CKS).

🧠 Introduction & Pathophysiology

Chronic liver disease results from sustained injury to hepatocytes and/or biliary epithelium, triggering inflammation and activation of hepatic stellate cells, which drive extracellular matrix deposition and fibrosis. Progression from fibrosis to cirrhosis alters hepatic architecture, leading to portal hypertension, synthetic dysfunction (coagulopathy, hypoalbuminaemia), and impaired metabolism. Ongoing cholestasis in biliary diseases further promotes bile acid toxicity and fat‑soluble vitamin deficiency. Immune dysregulation and genetic predisposition modulate susceptibility to injury and fibrosis.

🧭 Common Aetiologies (UK Practice)

• Alcohol‑related liver disease (ARLD): cumulative toxic injury
• Viral hepatitis: HBV, HCV (screening important)
• Metabolic dysfunction‑associated steatotic liver disease (MASLD/NAFLD): obesity, T2DM, dyslipidaemia
• Autoimmune liver diseases: AIH, PBC, PSC, overlap syndromes
• Genetic / metabolic: haemochromatosis, Wilson’s disease, A1AT deficiency
• Drug‑induced: methotrexate, amiodarone, isoniazid, herbal supplements
• Cholestatic conditions, vascular (Budd–Chiari), cryptogenic

🔍 Clinical Presentation

• Often asymptomatic early
• Fatigue, malaise, weight loss
• Right upper quadrant discomfort
• Jaundice, pruritus, steatorrhoea (cholestatic disease)
• Signs of portal hypertension: spider naevi, palmar erythema, caput medusae
• Asterixis, encephalopathy, ascites (advanced disease)

🧪 Initial Assessment (Primary Care)

• History: alcohol use (units/week), medications/herbals, viral risk (travel, tattoos, blood exposure), family history
• Exam: hepatomegaly, splenomegaly, stigmata of chronic liver disease (clubbing, palmar erythema)
• Baseline tests:
  • FBC, LFTs (ALT, AST, ALP, GGT, bilirubin), albumin
  • Coagulation (INR), platelets
  • Glucose/HbA1c, lipids
  • Renal function & electrolytes

📉 Non‑invasive Markers & Risk Stratification

• Fibrosis scoring: FIB‑4, APRI — use readily in primary care to triage risk
• Elastography (transient elastography) → assesses fibrosis severity
• NICE CKS: refer for specialist assessment if high fibrosis risk or abnormal scores

🧪 Aetiology‑Specific Testing

• Viral serology: HBsAg, anti‑HBc, HCV Ab + PCR if positive
• Autoimmune markers: ANA, SMA, AMA, IgG/IgM (AIH/PBC/PSC panel)
• Metabolic: ferritin/iron studies, caeruloplasmin (Wilson), A1AT levels
• Ultrasound: steatosis, nodularity, biliary dilatation

📊 Interpretation Pearls

• AST:ALT >2 → suggestive of alcohol‑related liver disease (ARLD)
• High ALP/GGT → cholestatic pattern → PBC/PSC or obstruction
• Isolated AST elevation in muscle disease → check CK

🎯 NICE‑Aligned Management Strategies

🍺 Alcohol‑related Liver Disease

• Abstinence support, brief interventions, referral to addiction services
• Manage malnutrition, micronutrient deficiency (thiamine), treat complications
• Consider pharmacotherapy for alcohol dependence where appropriate

🏥 MASLD / NAFLD

• Weight loss (7–10%), exercise, manage T2DM & dyslipidaemia
• Statin therapy safe and encouraged if indicated
• Assess for advanced fibrosis (elastography) and refer if high risk

🧬 Autoimmune Liver Diseases

Refer to autoimmune table above (AIH, PBC, PSC, overlap syndromes) for disease‑specific therapy and monitoring.

🦠 Viral Hepatitis

• HBV: antiviral therapy guided by viral load & fibrosis
• HCV: direct‑acting antivirals (DAAs) — curative regimens; referral for treatment
• Vaccinate contacts (HBV) where appropriate

🧠 Cirrhosis & Portal Hypertension

• Surveillance for varices and HCC per NICE/BSG guidelines
• Ascites management: salt restriction, diuretics; consider paracentesis
• Spontaneous bacterial peritonitis (SBP) prophylaxis and treatment
• Hepatic encephalopathy: lactulose ± rifaximin

📆 Monitoring & Follow‑up

• LFTs, full blood count every 3–6 months (or more frequently if unstable)
• Ultrasound liver ± AFP 6‑monthly if cirrhosis
• Bone health assessment if cholestatic disease or prolonged steroids

🚨 Red Flags / Urgent Referral

• Jaundice with rising bilirubin
• Bleeding varices, encephalopathy, acute ascites
• Weight loss with suspicious features (e.g., cachexia, anorexia)
• Child‑Pugh B/C or decompensation signs
• Suspected HCC or rapidly rising AFP

📚 Patient Education (UK Focus)

• Alcohol unit guidance and safe levels
• Benefits of weight loss and exercise for steatosis
• Importance of vaccinations
• Symptom awareness: confusion, abdominal distension, melena, haematemesis

📚 NICE References

• NICE NG50: Cirrhosis in over 16s: assessment and management
• NICE CKS – Liver disease: Chronic liver disease overview
• NICE NG145: Non‑alcoholic fatty liver disease
• NICE NG196: Viral hepatitis B and C
• NICE QS187: Chronic liver disease quality standard
• BSG Guidelines (linked for varices, HCC, PSC surveillance)

💡 Chronic liver disease often develops silently — a high index of suspicion, careful history (especially alcohol, metabolic risk factors, viral exposure), and early fibrosis assessment improve outcomes. Referral to hepatology is indicated for moderate or advanced disease, decompensation, or if aetiology is unclear.